Ara-290 (Cibinetide) is an 11-amino-acid peptide derived from erythropoietin designed to selectively target the innate repair receptor (IRR) without activating erythropoiesis. Research laboratories can source HPLC/MS-verified Ara-290 directly from PX1 Research, supported by lot-specific certificates of analysis and US-based ISO 17025 testing standards.
Ara-290 (Cibinetide) is an 11-amino-acid peptide derived from erythropoietin designed to selectively target the innate repair receptor (IRR) without activating erythropoiesis. Research laboratories can source HPLC/MS-verified Ara-290 directly from PX1 Research, supported by lot-specific certificates of analysis and US-based ISO 17025 testing standards.
Ara-290, also referred to in preclinical literature as Cibinetide or pyroglutamate helix B surface peptide (pHBSP), is a synthetic 11-amino-acid peptide engineered from the spatial structure of erythropoietin (EPO). Unlike native EPO, which primarily stimulates erythropoiesis via homodimeric EPO receptor signaling, Ara-290 was rationally designed to interact exclusively with the heterodimeric innate repair receptor (IRR). This receptor complex, composed of an EPO receptor monomer and a common beta subunit (CD131), is upregulated across endothelial, neuronal, and parenchymal tissues following cellular stress or tissue injury.
Researchers looking to buy Ara-290 for laboratory experimentation utilize the compound to investigate pathways governing tissue defense, inflammatory resolution, and cellular protection. Because Ara-290 lacks affinity for the classical homodimeric EPO receptor, preclinical assays demonstrate no activation of hematopoiesis, making it a specialized chemical probe for isolating tissue repair signaling from red blood cell production. Detailed literature regarding its synthetic derivation and receptor affinity is cataloged within our comprehensive research hub.
The molecular architecture of Ara-290 is derived specifically from Helix B of the erythropoietin molecule. Structural biology investigations revealed that the tissue-protective properties of EPO are physically distinct from its hematopoietic domain. Helix B contains the key contact residues responsible for binding to the CD131 heterodimer. Ara-290 condenses this functional sequence into an 11-residue linear peptide with N-terminal pyroglutamic acid modification to enhance chemical stability during in vitro research.
With a molecular weight of approximately 1257.4 Da, Ara-290 presents unique physicochemical properties during high-performance liquid chromatography (HPLC) and mass spectrometry (MS) characterization. The absence of tertiary folding required by full-length recombinant EPO allows synthetic Ara-290 to be manufactured under stringent solid-phase peptide synthesis (SPPS) protocols, ensuring exceptional lot-to-lot consistency when sourcing from a accredited US manufacturer.
The primary mechanism of action for Ara-290 centers on its selective agonism of the innate repair receptor (EPOR-CD131 heterodimer). In uninjured or homeostatic tissue, expression of the CD131 subunit remains minimal. However, upon exposure to inflammatory cytokines such as TNF-alpha, IL-1beta, or oxidative stress, tissue cells rapidly translocate CD131 to the plasma membrane, assembling the functional IRR complex.
Preclinical studies indicate that binding of Ara-290 to the IRR triggers downstream phosphorylation cascades, including the JAK2/STAT3 and Akt/PI3K pathways. Activation of these cascades suppresses nuclear factor kappa B (NF-kB) translocation, thereby dampening pro-inflammatory cytokine transcription while promoting anti-apoptotic gene expression. Researchers studying signal transduction frequently source Ara-290 alongside other regulatory peptides available in our main peptides directory to map cross-talk between tissue repair networks.
Extensive in vitro assays and animal models have evaluated Ara-290 for its capacity to attenuate acute and chronic inflammatory responses. In murine models of systemic inflammation, administration of Ara-290 demonstrated significant reductions in circulating serum levels of TNF-alpha, IL-6, and macrophage inflammatory protein-2 (MIP-2). The mechanism appears to involve direct modulation of macrophage activation states, shifting phenotypes from pro-inflammatory M1 dominance toward reparative M2 signaling.
Furthermore, preclinical research utilizing isolated vascular endothelial cell cultures shows that Ara-290 exposure reduces leukocyte adhesion molecule expression (ICAM-1 and VCAM-1). This reduction inhibits transendothelial migration of inflammatory cells into injured parenchymal tissue, preserving structural microvascular integrity during ischemic or toxic insults.
In neurobiological research, Ara-290 has been evaluated within rodent models of peripheral neuropathy and metabolic stress. Preclinical models of small-fiber nerve damage indicate that Ara-290 exposure supports neurite outgrowth and intraepidermal nerve fiber density preservation. These neuroprotective observations correlate with reduced activation of spinal microglial cells and decreased release of neuroinflammatory mediators.
In renal and cardiac ischemia-reperfusion models, preclinical data show that Ara-290 mitigates apoptotic cell death in tubular epithelial cells and cardiomyocytes. By stabilizing mitochondrial membrane potential and reducing reactive oxygen species (ROS) accumulation, the peptide preserves organ functionality under experimental metabolic stress protocols. Laboratory groups interested in institutional procurement can establish dedicated accounts through our wholesale lab portal.
When evaluating repair and protective signaling pathways, researchers frequently compare Ara-290 to other preclinical compounds such as BPC-157 and TB-500. While BPC-157 works primarily through focal adhesion kinase (FAK) signaling and nitric oxide pathway modulation, and TB-500 operates via actin sequestration (G-actin binding), Ara-290 is unique in its specific activation of the EPOR-CD131 heteroreceptor.
A detailed comparison of these mechanisms highlights their distinct experimental utilities: BPC-157 research overview details gastrointestinal and musculoskeletal fibroblast responses, whereas Ara-290 focuses specifically on neuro-inflammatory resolution and vascular endothelial defense. Utilizing multiple complementary compounds enables researchers to isolate receptor-specific effects within complex co-culture or animal tissue models.
When acquiring research compounds, analytical rigor is essential for data reproducibility. PX1 Research subjects every lot of Ara-290 to rigorous third-party verification performed by independent ISO 17025 accredited laboratories. Purity is validated via Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC), ensuring a minimum purity threshold of 99.0%.
Mass Spectrometry (ESI-MS) is conducted in parallel to confirm precise identity by verifying the exact molecular weight (1257.4 Da) and theoretical fragmentation pattern. Additionally, because Ara-290 is frequently utilized in cell culture and sensitive animal models, every batch undergoes chromogenic Limulus Amebocyte Lysate (LAL) testing to ensure bacterial endotoxin levels remain strictly below standard research limits (<0.01 EU/mg). Review our technical guide on peptide purity verification standards for deep technical methodology.
Ara-290 is supplied as a lyophilized (freeze-dried) cake or powder to ensure maximal structural stability during transport. Prior to use in laboratory assays, the compound must be reconstituted using sterile, laboratory-grade solvents under a laminar flow hood using aseptic technique.
For standard in vitro or biochemical assays, Bacteriostatic Water (0.9% benzyl alcohol) or sterile normal saline (0.9% NaCl) is recommended. The lyophilized powder should be allowed to reach room temperature before adding the solvent along the internal vial wall. Gentler rotational swirling is recommended; rigorous vortexing must be avoided to prevent mechanical shearing or aggregation of the peptide chain. Once fully dissolved, stock solutions should be aliquoted into single-use microcentrifuge tubes to prevent repeated freeze-thaw cycles.
Proper storage conditions are vital to maintain the structural integrity of synthetic peptides over extended research timelines. Upon arrival at your laboratory facility, sealed vials of lyophilized Ara-290 should be stored in a freezer maintained at -20°C or -80°C for long-term storage. Under these desiccated freezer conditions, the peptide remains stable for up to 24 months.
Reconstituted liquid solutions should be stored at 2°C to 8°C and utilized within 14 days if prepared with bacteriostatic water. If reconstituted in sterile unpreserved water or buffer solutions, liquid aliquots should be used immediately or stored frozen at -80°C. Avoid exposing reconstituted Ara-290 to direct light or elevated temperatures, as oxidation of sensitive amino acid residues can induce chemical degradation.
Selecting a reliable supplier for research-grade peptides requires verifying manufacturing provenance, quality control protocols, and shipping efficiency. PX1 Research synthesizes Ara-290 within state-of-the-art US-based GMP-compliant facilities. Every production run undergoes complete lot traceability, ensuring that analytical certificates of analysis match the precise material delivered to your laboratory.
All orders ship directly from centralized distribution facilities located in California and Arizona. Orders placed Monday through Friday prior to cutoff times ship same-day, mitigating environmental exposure and transit delays. Research facilities seeking high-purity compounds backed by full analytical transparency can safely place orders directly through our secure catalog or coordinate volume procurement via our dedicated account managers.
What is the sequence and molecular weight of Ara-290?
Ara-290 (Cibinetide) is an 11-amino-acid peptide derived from Helix B of erythropoietin. Its chemical sequence is pyroGlu-Glu-Gln-Glu-Ala-Val-Glu-Ser-Leu-Leu-Glu, with a theoretical molecular weight of approximately 1257.4 Da.
How does Ara-290 differ from erythropoietin (EPO)?
While EPO binds to the homodimeric EPO receptor to stimulate erythropoiesis (red blood cell production), Ara-290 selectively targets the heterodimeric innate repair receptor (EPOR-CD131). Preclinical data show Ara-290 does not stimulate hematopoiesis or alter hematocrit levels.
Is Ara-290 approved for human medical use or clinical treatment?
No. Ara-290 supplied by PX1 Research is strictly designated for laboratory research use only (RUO). It is not intended for clinical, therapeutic, human, or veterinary application.
What purity levels are guaranteed for Ara-290 from PX1 Research?
PX1 Research guarantees a minimum purity of 99.0% for Ara-290, confirmed via independent ISO 17025 third-party RP-HPLC and mass spectrometry analysis. A lot-specific COA is provided with every order.
How should lyophilized Ara-290 be stored upon receipt?
Lyophilized Ara-290 should be stored at -20°C or -80°C upon arrival. Stored in a desiccated freezer environment, the peptide retains integrity for up to 24 months.
What solvent is recommended for reconstituting Ara-290 in lab protocols?
Reconstitution is typically performed using sterile laboratory-grade Bacteriostatic Water or sterile 0.9% Sodium Chloride injection solution under aseptic cleanroom conditions.
Are endotoxin levels tested for PX1 Research Ara-290 lots?
Yes. Every lot of Ara-290 undergoes LAL chromogenic endotoxin testing to confirm levels remain below standard research specifications (<0.01 EU/mg), making it suitable for sensitive cell assays.
Where does PX1 Research ship Ara-290 orders from?
All orders are fulfilled directly from domestic facilities located in California and Arizona, with same-day shipping available for orders processed Monday through Friday.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.